Table 1. Patient characteristics and transplant variables.
| All Patients (n = 190) | Survivors (n = 117) | Non survivors (n = 73) | p value | |
| Age (years) | 51±13 | 50±13 | 52±13 | 0.300 |
| Male gender | 115 (60.5) | 61 (52.1) | 54 (73.9) | 0.002 |
| Body mass index (kg/m2) | 24±5 | 25±5 | 23±4 | 0.003 |
| Comorbidities | ||||
| Hypertension | 152 (80.0) | 99 (84.6) | 53 (72.6) | 0.040 |
| Diabetes mellitus | 61 (32.1) | 39 (33.3) | 22 (30.1) | 0.600 |
| CAD | 35 (18.4) | 24 (20.5) | 11 (15.0) | 0.300 |
| Stroke | 8 (4.2) | 6 (5.1) | 2 (2.7) | 0.700 |
| CHF | 5 (2.6) | 3 (2.5) | 2 (2.7) | 1.000 |
| Hepatitis C | 13 (6.8) | 7 (5.9) | 6 (8.2) | 0.500 |
| Hepatitis B | 6 (3.1) | 3 (2.5) | 3 (4.1) | 0.600 |
| COPD | 6 (3.1) | 1 (0.8) | 5 (6.8) | 0.030 |
| ESRD etiology | 0.220 | |||
| Undetermined | 67 (35.2) | 41 (35.0) | 26 (35.6) | |
| Glomerulonephritis | 50 (26.3) | 33 (28.2) | 17 (23.2) | |
| Diabetes mellitus | 36 (18.9) | 18 (15.3) | 18 (24.6) | |
| Hypertension | 28 (14.7) | 21 (17.9) | 7 (9.5) | |
| Urologic disease | 9 (4.7) | 4 (3.4) | 5 (6.8) | |
| Dialysis modality before transplant | 0.480 | |||
| Preemptive | 8 (4.2) | 7 (5.9) | 1 (1.3) | |
| Hemodialysis | 153 (80.5) | 91 (77.7) | 62 (84.9) | |
| Peritoneal | 21 (11.0) | 14 (11.9) | 7 (9.5) | |
| Hemodialysis/peritoneal | 8 (4.2) | 5 (4.2) | 3 (4.1) | |
| Time of dialysis (months) | 34 (18–60) | 32 (18–60) | 36 (24–68) | 0.170 |
| Donor type | 0.190 | |||
| Deceased | 122 (64.2) | 71 (60.6) | 51 (69.8) | |
| Living | 68 (35.8) | 46 (39.4) | 22 (30.2) | |
| Donor gender a | 0.330 | |||
| Female | 71 (42.0) | 43 (40.6) | 28 (44.5) | |
| Male | 98 (58.0) | 63 (59.4) | 35 (55.5) | |
| Deceased donor b | ||||
| Cause of death c | 0.930 | |||
| Traumatic brain injury | 33 (28.0) | 21 (30.0) | 12 (25.0) | |
| Subarachnoid hemorrhage | 20 (16.9) | 12 (17.1) | 8 (16.6) | |
| Stroke | 56 (47.5) | 32 (45.7) | 24 (50.0) | |
| Others | 9 (7.6) | 5 (7.2) | 4 (8.4) | |
| Panel reactive antibodies d | 0.660 | |||
| 0–50% | 93 (84.5) | 55 (83.3) | 38 (86.3) | |
| >51% | 17 (15.5) | 11 (16.7) | 6 (13.6) | |
| Final creatinine e | 0.210 | |||
| <1.5 mg/dL | 31 (32.6) | 21 (35.5) | 10 (27.7) | |
| ≥1.5 mg/dL | 64 (67.4) | 38 (64.5) | 26 (72.3) | |
| Cold ischemia time (hours) f | 23 (20–27) | 23 (20–28) | 22 (20–27) | 0.630 |
| Expanded criteria donor | 31 (26.3) | 13 (18.6) | 18 (37.5) | 0.020 |
| Delayed graft function | 82 (43.3) | 44 (37.6) | 38 (52.7) | 0.040 |
| Thymoglobulin use g | 54 (28.5) | 34 (29.0) | 20 (27.7) | 0.870 |
| CMV disease treated | 68 (35.9) | 41 (35.0) | 27 (37.5) | 0.750 |
| Current immunosuppression h | 0.460 | |||
| TAC+PRED+AZA | 31 (16.3) | 16 (13.6) | 15 (20.5) | |
| TAC+PRED+MF | 70 (36.8) | 48 (41.0) | 22 (30.1) | |
| CSA+PRED+AZA | 17 (8.9) | 12 (10.2) | 5 (6.8) | |
| CSA+PRED+MF | 7 (3.6) | 4 (3.4) | 3 (4.1) | |
| TAC/CSA+PRED+EVR/SRL | 4 (2.1) | 3 (2.5) | 1 (1.7) | |
| SRL/EVR+PRED+MF | 9 (4.7) | 4 (3.4) | 5 (6.8) | |
| Others | 51 (26.8) | 30 (25.6) | 21 (28.7) | |
| Time between transplant and sepsis (years) | 2.1 (0.6–7.2) | 2.3 (0.6–7.8) | 1.6 (0.6–7.0) | 0.600 |
| Acute rejection | 55 (28.9) | 34 (29.0) | 21 (28.7) | 0.960 |
| Time rejection-sepsis (days) i | 312 (130–776) | 331(115–817) | 282 (152–849) | 0.900 |
CAD coronary artery disease, CHF: congestive heart failure, COPD: chronic obstructive pulmonary disease, ESRD: end-stage renal disease, CMV: cytomegalovirus, TAC: tacrolimus, PRED: prednisone, AZA: azathioprine, MF: mycophenolate, CSA: cyclosporine, EVR: everolimus, SRL sirolimus.
a) 21 missing data,
b) 122 deceased donors,
c) 4 missing data,
d) 12 missing data,
e) final creatinine refers to the donors' last serum creatinine level, 27 missing data,
f) 3 missing data,
g) patients who used thymoglobulin for treating rejection and/or induction in transplantation,
h) 1 missing data and i) time between the occurrence of rejection and sepsis (total of patients with rejection, 55 patients, 3 patients among the survivors and 6 among the non-survivors were excluded for missing data). The results are expressed as number (%) or median (IQR, 25%–75%) or mean ± standard deviation. Chi-squared test, Mann-Whitney U-test, and Student's t-test (univariate analysis).